Tocotrienol

Summary

Tocotrienol (CHEMBL120643) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including ovarian cancer and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 13
• Chemistry: 382.6 Da · C26H38O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL120643
Name	Tocotrienol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9929901
Molecular formula	C26H38O2
Molecular weight	382.6
InChIKey	GJJVAFUKOBZPCB-ZGRPYONQSA-N

SMILES: CC(=CCC/C(=C/CC/C(=C/CCC1(CCC2=C(O1)C=CC(=C2)O)C)/C)/C)C

IUPAC name: 2-methyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol

Also known as: Alpha tocotrienol, Tocotrienol, alpha, SID124897770, TOCOTRIENOL

Patent coverage: 40 distinct patent families (93 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	2	MONDO:0008170	MONDO:0008170
breast neoplasm	2	MONDO:0021100	MONDO:0007254
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
Not specified	6
PHASE2	5
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01973400	PHASE3	COMPLETED	Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
NCT02263924	PHASE3	UNKNOWN	Stroke and Tocotrienol: Unique Role in Neuroprotection
NCT02581085	PHASE2	ACTIVE_NOT_RECRUITING	Tocotrienol Against the Progression of End Stage Liver Disease
NCT04245865	PHASE2	ACTIVE_NOT_RECRUITING	Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
NCT02705300	PHASE2	COMPLETED	Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
NCT04175470	PHASE2	COMPLETED	Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
NCT04496492	PHASE2	COMPLETED	Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.
NCT00889434	Not specified	COMPLETED	Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)
NCT00893724	Not specified	UNKNOWN	Supplemental Adjuvants for Intracellular Nutrition and Treatment
NCT01185769	Not specified	COMPLETED	Study of Tocotrienol Absorption and Distribution Under Different Fat Status
NCT01579227	Not specified	UNKNOWN	Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound
NCT01858311	Not specified	COMPLETED	Nutrition Blood Outcomes Following Tocotrienol N2B
NCT05471453	Not specified	COMPLETED	Effectiveness of Adjuvant Supplements Prior to in IVF

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).